Identification

Name
Barnidipine
Accession Number
DB09227
Type
Small Molecule
Groups
Approved
Description

Barnidipine is a long-acting novel calcium antagonist that belongs to the dihydropyridine (DHP) group of calcium channel blockers. Used in the treatment of hypertension, barnidipine displays high affinity for the calcium channels of the smooth muscle cells in the vascular wall [6] and selectivity against cardiovascular L-type calcium channels [1]. Barnidipine contains two chiral centres thus can have four possible enantiomers. The active component is composed of a single optical isomer (3'S, 4S configuration), which is the most potent and longest-acting of the four enantiomers [3]. Compared to several other calcium antagonists which are racemates, the barnidipine compound consisting of a single enantiomer may offer a high degree of pharmacological selectivity [3].

According to a dose-ranging, multicentre, placebo-controlled, double-blind study in patients with mild to moderate hypertension, the antihypertensive response from barnidipine treatment was maintained after a 1-year and 2-year follow-up period in 91% of the patients who had an initial response to the drug [1]. In two European multicentre randomized, double-blind trials, barnidipine was shown to possess equivalent antihypertensive efficacy to amlodipine and nitrendipine, but produced fewer class-specific side-effects [4]. It also demonstrated clinical efficacy which is similar to that of atenolol, enalapril and hydrochlorothiazide [1].

It is available in modified-release oral tablets under the brand name Vasexten to be taken once daily in the morning. Barnidipine has a gradual onset of action and is shown to be well tolerated in patients. It does not produce reflex tachycardia [1].

Structure
Thumb
Synonyms
  • Mepirodipine
Categories
UNII
2VBY96ASWJ
CAS number
104713-75-9
Weight
Average: 491.544
Monoisotopic: 491.205635666
Chemical Formula
C27H29N3O6
InChI Key
VXMOONUMYLCFJD-DHLKQENFSA-N
InChI
InChI=1S/C27H29N3O6/c1-17-23(26(31)35-3)25(20-10-7-11-21(14-20)30(33)34)24(18(2)28-17)27(32)36-22-12-13-29(16-22)15-19-8-5-4-6-9-19/h4-11,14,22,25,28H,12-13,15-16H2,1-3H3/t22-,25-/m0/s1
IUPAC Name
3-(3S)-1-benzylpyrrolidin-3-yl 5-methyl (4S)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
SMILES
COC(=O)C1=C(C)NC(C)=C([C@H]1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)O[C@H]1CCN(CC2=CC=CC=C2)C1

Pharmacology

Indication

Indicated for the treatment of mild to moderate essential hypertension and management of chronic stable angina.

Pharmacodynamics

Barnidipine reduces peripheral resistance and lowers blood pressure. The chronic use of the drug is not reported to lead to an increase in basic heart frequency. The antihypertensive effects of barnidipine are reported to remain during the entire 24-hour dose interval. Barnidipine does not exert any negative effect on serum lipids profile, glucose level or blood electrolytes [6].

Mechanism of action

Barnidipine is a lipophilic 1,4-dihydropyridine calcium antagonist that is characterized by a slow onset of action and a strong and long-lasting binding to the L-type calcium channels [6]. It displays high affinity for the channels expressed in the smooth muscle cells in the vascular wall. Its main mechanism of action arises from the reduction of peripheral vascular resistance secondary to its vasodilatory actions.

Calcium ion influx via L-subtype ‘voltage-operated’ channels in the excitable membranes of the smooth muscle cells promotes the formation of calcium-dependent formation of cross-bridges between myosin and actin which are the two major contractile proteins that drive contraction. By blocking the L-type 'voltage-dependent' calcium channels, barnidipine selectively blocks the calcium ion influx in the smooth muscle cells and inhibits the activation of contractile proteins [3]. It is suggested that barnidipine displays a high affinity to the inactivated state of the channel [5]. Like other dihydropyridine calcium antagonists, barnidipine is predicted to interact with the alpha 1-C subunit of the L-type calcium channels. Alpha 1-C subunit of the channel is predicted to reside within the bilayer or channel pore at a location closer to the extracellular rather than the intracellular face of the membrane [A31569, A19705]. Its lipophilicity is likely a reason why barnidipine displays a slow onset and long duration of action. Being a highly lipophilic molecule with an octanol/water partition coefficient of 2000, barnidipine is expected to accumulate in the cell membrane and consequently, gains access to its target receptor in a slow manner [3].

TargetActionsOrganism
AVoltage-dependent L-type calcium channel subunit alpha-1C
antagonist
Human
Absorption

Following a single, modified-release dose of 10mg barnidipine, the peak plasma concentration was approximately 0.48 µg/L and the area under the curve (AUC) was 2.85 µg/Lxh [1]. The peak plasma concentrations are reached within 5 to 6 hours after oral administration of 20mg barnidipine. While the plasma concentrations of the drug may vary between individuals, the absolute bioavailability of the barnidipine is approximately 1.1% due to extensive first-pass hepatic metabolism [6]. After repeated administration of 20mg barnidipine to healthy individuals, the concomitant intake of food did not have a statistically significant effect on the AUC, Cmax or half-life of the drug [6].

Volume of distribution

After administration of single oral doses of radiolabelled barnidipine in rats, levels of radioactivity were found to be higher in the kidney, liver and gastrointestinal tract than in plasma, whereas the brain showed the lowest level of radioactivity. The drug was also detectable in the breast milk [1].

Protein binding

In vitro binding of barnidipine with plasma proteins was between 92.4 and 98.9%, and was mainly with albumin [1]. Barnidipine binds at the rate of 26-32% to human erythrocytes. In addition to serum albumin, barnidipine also binds to α1 acid glycoprotein and high density lipoproteins. To a much lesser extent, binding to γ-globulin takes place [6].

Metabolism

Barnidipine is expected to undergo hepatic metabolism. The primary metabolism of barnidipine involves the oxidation of the 1,4-dihydropyridine ring and hydrolysis of the methyl ester. Secondary metabolism involves N-debenzylization of the side chain, hydrolysis of the N-benzylpyrrolidine ester, and reduction of the nitro group [2]. Both the primary and secondary metabolic pathways are mediated by the CYP3A isoenzyme family and the metabolites formed are pharmacologically inactive [1, 6].

Route of elimination

Barnidipine and its metabolites are metabolized into feces (60%), urine (40%) and breath (1%) [6]. Following a single dose administration of barnidipine ranging from 5 to 20mg in healthy volunteers, urinary excretion of unchanged drug was negligible (≤0.003% of an administered dose) [1].

Half life

In a two-compartment analytical model, the median terminal elimination half life of barnidipine was 20 hours after repeated administration [6].

Clearance
Not Available
Toxicity

Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity to reproduction [6]. Oral LD50 in rat and mouse are 105mg/kg and 108mg/kg, respectively [MSDS].

In general, the clinical symptoms from overdose of calcium antagonists appear within 30 to 60 minutes of after administration of a dose five to ten times higher than the therapeutic dose. Possible symptoms that may develop include hypotension, electrophysiological effects (sinus bradycardia, prolonged AV conduction, second and third degree AV block, tachycardia), effects on the central nervous system (drowsiness, confusion and, rarely, convulsions), gastrointestinal symptoms (nausea and vomiting) and metabolic effects (hyperglycaemia) [6].

In the case of intoxication, symptomatic treatment and continuous ECG monitoring in the clinical setting are recommended. In the case of overdose, gastric lavage is strongly recommended. An intravenous (dosage 0.2 ml/kg body weight) injection of calcium (preferably 10 ml of a calcium chloride solution of 10%) should be given over a period of 5 minutes, up to a total dose of 10 ml 10%. Contractility of the myocardium, sinus rhythm and atrioventricular conduction will thus be improved. The treatment can be repeated every 15 to 20 minutes (up to a total of 4 doses) based on the patient’s response. Calcium levels should be checked [6].

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2-HYDROXY-1,4-NAPHTHOQUINONEThe therapeutic efficacy of 2-HYDROXY-1,4-NAPHTHOQUINONE can be increased when used in combination with Barnidipine.Experimental
2-mercaptobenzothiazoleThe therapeutic efficacy of 2-mercaptobenzothiazole can be increased when used in combination with Barnidipine.Vet Approved
9-(N-methyl-L-isoleucine)-cyclosporin AThe serum concentration of Barnidipine can be increased when it is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.Investigational
AcebutololAcebutolol may increase the antihypertensive activities of Barnidipine.Approved, Investigational
AcepromazineThe risk or severity of hypotension can be increased when Acepromazine is combined with Barnidipine.Approved, Vet Approved
AldesleukinThe risk or severity of adverse effects can be increased when Barnidipine is combined with Aldesleukin.Approved
AlfuzosinThe risk or severity of hypotension can be increased when Alfuzosin is combined with Barnidipine.Approved, Investigational
AliskirenAliskiren may increase the antihypertensive activities of Barnidipine.Approved, Investigational
AlisporivirThe serum concentration of Barnidipine can be increased when it is combined with Alisporivir.Investigational
AlprenololAlprenolol may increase the antihypertensive activities of Barnidipine.Approved, Withdrawn
AmbrisentanAmbrisentan may increase the antihypertensive activities of Barnidipine.Approved, Investigational
AmifostineThe risk or severity of adverse effects can be increased when Amifostine is combined with Barnidipine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Barnidipine is combined with Amiloride.Approved
AmiodaroneThe serum concentration of Barnidipine can be increased when it is combined with Amiodarone.Approved, Investigational
AmitriptylineThe risk or severity of hypotension can be increased when Amitriptyline is combined with Barnidipine.Approved
AmlodipineAmlodipine may increase the antihypertensive activities of Barnidipine.Approved
AmobarbitalThe metabolism of Barnidipine can be increased when combined with Amobarbital.Approved, Illicit
AmorolfineThe therapeutic efficacy of Amorolfine can be increased when used in combination with Barnidipine.Approved, Investigational
AmoxapineThe risk or severity of hypotension can be increased when Amoxapine is combined with Barnidipine.Approved
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Barnidipine.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Barnidipine is combined with Amyl Nitrite.Approved
AnidulafunginThe therapeutic efficacy of Anidulafungin can be increased when used in combination with Barnidipine.Approved, Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Barnidipine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Apraclonidine.Approved
AripiprazoleAripiprazole may increase the hypotensive activities of Barnidipine.Approved, Investigational
ArotinololThe risk or severity of hypotension, conduction block, and bradycardia can be increased when Arotinolol is combined with Barnidipine.Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Barnidipine.Approved, Investigational
ArtemetherThe therapeutic efficacy of Artemether can be increased when used in combination with Barnidipine.Approved
AsenapineThe risk or severity of hypotension can be increased when Asenapine is combined with Barnidipine.Approved
AtazanavirThe serum concentration of Barnidipine can be increased when it is combined with Atazanavir.Approved, Investigational
AtenololAtenolol may increase the antihypertensive activities of Barnidipine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Barnidipine is combined with Azilsartan medoxomil.Approved, Investigational
Bafilomycin A1The therapeutic efficacy of Bafilomycin A1 can be increased when used in combination with Barnidipine.Experimental
BarbexacloneBarbexaclone may increase the hypotensive activities of Barnidipine.Experimental
BarbitalThe metabolism of Barnidipine can be increased when combined with Barbital.Illicit
BenazeprilBenazepril may increase the antihypertensive activities of Barnidipine.Approved, Investigational
BendroflumethiazideBendroflumethiazide may increase the antihypertensive activities of Barnidipine.Approved
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be increased when used in combination with Barnidipine.Approved, Investigational
BepridilBepridil may increase the antihypertensive activities of Barnidipine.Approved, Withdrawn
BetaxololBetaxolol may increase the antihypertensive activities of Barnidipine.Approved, Investigational
BethanidineBethanidine may increase the antihypertensive activities of Barnidipine.Approved
BevantololThe risk or severity of hypotension can be increased when Bevantolol is combined with Barnidipine.Approved
BietaserpineBietaserpine may increase the antihypertensive activities of Barnidipine.Experimental
BifonazoleThe therapeutic efficacy of Bifonazole can be increased when used in combination with Barnidipine.Approved, Investigational
BimatoprostBimatoprost may increase the antihypertensive activities of Barnidipine.Approved, Investigational
BisoprololBisoprolol may increase the antihypertensive activities of Barnidipine.Approved
BoceprevirThe serum concentration of Barnidipine can be increased when it is combined with Boceprevir.Approved, Withdrawn
BortezomibThe risk or severity of adverse effects can be increased when Barnidipine is combined with Bortezomib.Approved, Investigational
BosentanBosentan may increase the antihypertensive activities of Barnidipine.Approved, Investigational
BQ-123BQ-123 may increase the antihypertensive activities of Barnidipine.Investigational
Brefeldin AThe therapeutic efficacy of Brefeldin A can be increased when used in combination with Barnidipine.Experimental
BretyliumBretylium may increase the antihypertensive activities of Barnidipine.Approved
BrexpiprazoleThe risk or severity of hypotension can be increased when Brexpiprazole is combined with Barnidipine.Approved, Investigational
BrimonidineBrimonidine may increase the antihypertensive activities of Barnidipine.Approved
BromocriptineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Bromocriptine.Approved, Investigational
BucindololThe risk or severity of hypotension can be increased when Bucindolol is combined with Barnidipine.Investigational
BumetanideThe risk or severity of adverse effects can be increased when Barnidipine is combined with Bumetanide.Approved
BunazosinThe risk or severity of hypotension can be increased when Bunazosin is combined with Barnidipine.Investigational
BupivacaineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Bupivacaine.Approved, Investigational
BupranololBupranolol may increase the antihypertensive activities of Barnidipine.Approved
ButenafineThe therapeutic efficacy of Butenafine can be increased when used in combination with Barnidipine.Approved
ButoconazoleThe therapeutic efficacy of Butoconazole can be increased when used in combination with Barnidipine.Approved
CadralazineCadralazine may increase the antihypertensive activities of Barnidipine.Experimental
CafedrineCafedrine may increase the antihypertensive activities of Barnidipine.Investigational
Calcium AcetateThe therapeutic efficacy of Barnidipine can be decreased when used in combination with Calcium Acetate.Approved, Investigational
Calcium CarbonateThe therapeutic efficacy of Barnidipine can be decreased when used in combination with Calcium Carbonate.Approved, Investigational
Calcium ChlorideThe therapeutic efficacy of Barnidipine can be decreased when used in combination with Calcium Chloride.Approved
Calcium CitrateThe therapeutic efficacy of Barnidipine can be decreased when used in combination with Calcium Citrate.Approved
Calcium glubionateThe therapeutic efficacy of Barnidipine can be decreased when used in combination with Calcium glubionate.Approved
Calcium GluceptateThe therapeutic efficacy of Barnidipine can be decreased when used in combination with Calcium Gluceptate.Approved
Calcium gluconateThe therapeutic efficacy of Barnidipine can be decreased when used in combination with Calcium gluconate.Approved, Vet Approved
Calcium lactateThe therapeutic efficacy of Barnidipine can be decreased when used in combination with Calcium lactate.Approved, Investigational, Vet Approved
Calcium lactate gluconateThe therapeutic efficacy of Barnidipine can be decreased when used in combination with Calcium lactate gluconate.Experimental
Calcium levulinateThe therapeutic efficacy of Barnidipine can be decreased when used in combination with Calcium levulinate.Approved, Experimental
Calcium pangamateThe therapeutic efficacy of Barnidipine can be decreased when used in combination with Calcium pangamate.Experimental
Calcium PhosphateThe therapeutic efficacy of Barnidipine can be decreased when used in combination with Calcium Phosphate.Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Barnidipine is combined with Canagliflozin.Approved
CandesartanCandesartan may increase the antihypertensive activities of Barnidipine.Experimental
Candesartan cilexetilCandesartan cilexetil may increase the antihypertensive activities of Barnidipine.Approved
CandicidinThe therapeutic efficacy of Candicidin can be increased when used in combination with Barnidipine.Withdrawn
CandoxatrilCandoxatril may increase the antihypertensive activities of Barnidipine.Experimental
Capric acidThe therapeutic efficacy of Capric acid can be increased when used in combination with Barnidipine.Experimental
CaptoprilCaptopril may increase the antihypertensive activities of Barnidipine.Approved
CarbetocinThe risk or severity of adverse effects can be increased when Barnidipine is combined with Carbetocin.Approved, Investigational
CarteololCarteolol may increase the antihypertensive activities of Barnidipine.Approved
CarvedilolCarvedilol may increase the antihypertensive activities of Barnidipine.Approved, Investigational
CaseinThe therapeutic efficacy of Barnidipine can be decreased when used in combination with Casein.Approved
CaspofunginThe therapeutic efficacy of Caspofungin can be increased when used in combination with Barnidipine.Approved
CeliprololCeliprolol may increase the antihypertensive activities of Barnidipine.Approved, Investigational
CeritinibThe serum concentration of Barnidipine can be increased when it is combined with Ceritinib.Approved
CeruleninThe therapeutic efficacy of Cerulenin can be increased when used in combination with Barnidipine.Approved
ChlorothiazideChlorothiazide may increase the antihypertensive activities of Barnidipine.Approved, Vet Approved
ChloroxineThe therapeutic efficacy of Chloroxine can be increased when used in combination with Barnidipine.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Chlorpromazine.Approved, Investigational, Vet Approved
ChlorthalidoneChlorthalidone may increase the antihypertensive activities of Barnidipine.Approved
CicletanineCicletanine may increase the antihypertensive activities of Barnidipine.Investigational
CiclopiroxThe therapeutic efficacy of Ciclopirox can be increased when used in combination with Barnidipine.Approved, Investigational
CilazaprilCilazapril may increase the antihypertensive activities of Barnidipine.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Cilnidipine.Approved, Investigational
CimetidineThe serum concentration of Barnidipine can be increased when it is combined with Cimetidine.Approved, Investigational
ClarithromycinThe serum concentration of Barnidipine can be increased when it is combined with Clarithromycin.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Clevidipine.Approved, Investigational
ClofarabineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Clofarabine.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Clomipramine.Approved, Investigational, Vet Approved
ClonidineClonidine may increase the antihypertensive activities of Barnidipine.Approved
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Barnidipine.Approved
CloranololCloranolol may increase the antihypertensive activities of Barnidipine.Experimental
ClotrimazoleThe therapeutic efficacy of Clotrimazole can be increased when used in combination with Barnidipine.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Clozapine.Approved
CobicistatThe serum concentration of Barnidipine can be increased when it is combined with Cobicistat.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Barnidipine is combined with Conivaptan.Approved, Investigational
CordycepinThe therapeutic efficacy of Cordycepin can be increased when used in combination with Barnidipine.Investigational
CryptenamineCryptenamine may increase the antihypertensive activities of Barnidipine.Approved
CurcuminThe serum concentration of Barnidipine can be increased when it is combined with Curcumin.Approved, Investigational
CyclopenthiazideCyclopenthiazide may increase the antihypertensive activities of Barnidipine.Experimental
CyclosporineThe serum concentration of Barnidipine can be increased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
CyclothiazideCyclothiazide may increase the antihypertensive activities of Barnidipine.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Barnidipine is combined with Dapagliflozin.Approved
DapiprazoleThe risk or severity of hypotension can be increased when Dapiprazole is combined with Barnidipine.Approved
DarunavirThe serum concentration of Barnidipine can be increased when it is combined with Darunavir.Approved
DebrisoquinDebrisoquin may increase the antihypertensive activities of Barnidipine.Approved, Investigational
DelaprilDelapril may increase the antihypertensive activities of Barnidipine.Investigational
DeserpidineDeserpidine may increase the antihypertensive activities of Barnidipine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Barnidipine is combined with Desflurane.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Dexmedetomidine.Approved, Vet Approved
DextroamphetamineThe risk or severity of hypotension can be increased when Dextroamphetamine is combined with Barnidipine.Approved, Illicit
DiazoxideDiazoxide may increase the antihypertensive activities of Barnidipine.Approved
DichloropheneThe therapeutic efficacy of Dichlorophene can be increased when used in combination with Barnidipine.Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Barnidipine is combined with Diclofenamide.Approved, Investigational
DiethylnorspermineDiethylnorspermine may increase the antihypertensive activities of Barnidipine.Investigational
DihydralazineDihydralazine may increase the antihypertensive activities of Barnidipine.Approved, Investigational
DiltiazemDiltiazem may increase the antihypertensive activities of Barnidipine.Approved, Investigational
DinutuximabThe risk or severity of adverse effects can be increased when Barnidipine is combined with Dinutuximab.Approved, Investigational
DipyridamoleThe risk or severity of adverse effects can be increased when Barnidipine is combined with Dipyridamole.Approved
DorzolamideDorzolamide may increase the antihypertensive activities of Barnidipine.Approved
DoxazosinDoxazosin may increase the antihypertensive activities of Barnidipine.Approved
DoxepinThe risk or severity of hypotension can be increased when Doxepin is combined with Barnidipine.Approved, Investigational
DronedaroneThe risk or severity of hypotension can be increased when Dronedarone is combined with Barnidipine.Approved
DroperidolThe risk or severity of hypotension can be increased when Droperidol is combined with Barnidipine.Approved, Vet Approved
DuloxetineBarnidipine may increase the orthostatic hypotensive activities of Duloxetine.Approved
EconazoleThe therapeutic efficacy of Econazole can be increased when used in combination with Barnidipine.Approved
EfavirenzThe serum concentration of Barnidipine can be decreased when it is combined with Efavirenz.Approved, Investigational
EfinaconazoleThe therapeutic efficacy of Efinaconazole can be increased when used in combination with Barnidipine.Approved
EfonidipineEfonidipine may increase the antihypertensive activities of Barnidipine.Approved, Investigational
EmpagliflozinThe risk or severity of adverse effects can be increased when Barnidipine is combined with Empagliflozin.Approved
EnalaprilEnalapril may increase the antihypertensive activities of Barnidipine.Approved, Vet Approved
EnalaprilatEnalaprilat may increase the antihypertensive activities of Barnidipine.Approved
EndralazineEndralazine may increase the antihypertensive activities of Barnidipine.Experimental
EpanololEpanolol may increase the antihypertensive activities of Barnidipine.Experimental
EpinephrineThe risk or severity of hypotension can be increased when Epinephrine is combined with Barnidipine.Approved, Vet Approved
EplerenoneThe risk or severity of adverse effects can be increased when Barnidipine is combined with Eplerenone.Approved
EpoprostenolEpoprostenol may increase the antihypertensive activities of Barnidipine.Approved
EprosartanEprosartan may increase the antihypertensive activities of Barnidipine.Approved
ErythromycinThe serum concentration of Barnidipine can be increased when it is combined with Erythromycin.Approved, Investigational, Vet Approved
EscitalopramThe risk or severity of hypotension can be increased when Escitalopram is combined with Barnidipine.Approved, Investigational
EsmololThe risk or severity of adverse effects can be increased when Barnidipine is combined with Esmolol.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Barnidipine is combined with Etacrynic acid.Approved, Investigational
FelodipineFelodipine may increase the antihypertensive activities of Barnidipine.Approved, Investigational
FenoldopamFenoldopam may increase the antihypertensive activities of Barnidipine.Approved
FenticonazoleThe therapeutic efficacy of Fenticonazole can be increased when used in combination with Barnidipine.Experimental
Ferulic acidFerulic acid may increase the antihypertensive activities of Barnidipine.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Barnidipine is combined with Fimasartan.Approved, Investigational
FluconazoleThe therapeutic efficacy of Fluconazole can be increased when used in combination with Barnidipine.Approved, Investigational
FlucytosineThe therapeutic efficacy of Flucytosine can be increased when used in combination with Barnidipine.Approved, Investigational
FlupentixolThe risk or severity of hypotension can be increased when Flupentixol is combined with Barnidipine.Approved, Investigational, Withdrawn
FlutrimazoleThe therapeutic efficacy of Flutrimazole can be increased when used in combination with Barnidipine.Experimental
FosinoprilFosinopril may increase the antihypertensive activities of Barnidipine.Approved
FurosemideThe risk or severity of adverse effects can be increased when Barnidipine is combined with Furosemide.Approved, Vet Approved
GlyphosateThe therapeutic efficacy of Glyphosate can be increased when used in combination with Barnidipine.Experimental
GriseofulvinThe therapeutic efficacy of Griseofulvin can be increased when used in combination with Barnidipine.Approved, Investigational, Vet Approved
GuanabenzGuanabenz may increase the antihypertensive activities of Barnidipine.Approved, Investigational
GuanadrelGuanadrel may increase the antihypertensive activities of Barnidipine.Approved
GuanazodineGuanazodine may increase the antihypertensive activities of Barnidipine.Experimental
GuanethidineGuanethidine may increase the antihypertensive activities of Barnidipine.Approved
GuanfacineGuanfacine may increase the antihypertensive activities of Barnidipine.Approved, Investigational
GuanoclorGuanoclor may increase the antihypertensive activities of Barnidipine.Experimental
GuanoxabenzGuanoxabenz may increase the antihypertensive activities of Barnidipine.Experimental
GuanoxanGuanoxan may increase the antihypertensive activities of Barnidipine.Experimental
HachimycinThe therapeutic efficacy of Hachimycin can be increased when used in combination with Barnidipine.Experimental
HaloproginThe therapeutic efficacy of Haloprogin can be increased when used in combination with Barnidipine.Approved, Withdrawn
HalothaneThe risk or severity of adverse effects can be increased when Barnidipine is combined with Halothane.Approved, Vet Approved
HexamethoniumHexamethonium may increase the antihypertensive activities of Barnidipine.Experimental
HexetidineThe therapeutic efficacy of Hexetidine can be increased when used in combination with Barnidipine.Approved, Investigational
HexobarbitalThe metabolism of Barnidipine can be increased when combined with Hexobarbital.Approved
HydralazineHydralazine may increase the antihypertensive activities of Barnidipine.Approved
HydrochlorothiazideHydrochlorothiazide may increase the antihypertensive activities of Barnidipine.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may increase the antihypertensive activities of Barnidipine.Approved, Investigational
IdelalisibThe serum concentration of Barnidipine can be increased when it is combined with Idelalisib.Approved
IloperidoneThe risk or severity of hypotension can be increased when Iloperidone is combined with Barnidipine.Approved
IloprostThe risk or severity of adverse effects can be increased when Barnidipine is combined with Iloprost.Approved, Investigational
ImidaprilImidapril may increase the antihypertensive activities of Barnidipine.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Imipramine.Approved
IndapamideIndapamide may increase the antihypertensive activities of Barnidipine.Approved
IndenololIndenolol may increase the antihypertensive activities of Barnidipine.Withdrawn
IndinavirThe serum concentration of Barnidipine can be increased when it is combined with Indinavir.Approved
IndoraminIndoramin may increase the antihypertensive activities of Barnidipine.Withdrawn
IrbesartanIrbesartan may increase the antihypertensive activities of Barnidipine.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Barnidipine is combined with Isocarboxazid.Approved
IsoconazoleThe therapeutic efficacy of Isoconazole can be increased when used in combination with Barnidipine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Barnidipine is combined with Isoflurane.Approved, Vet Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Barnidipine is combined with Isosorbide Dinitrate.Approved, Investigational
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Barnidipine is combined with Isosorbide Mononitrate.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Isoxsuprine.Approved, Withdrawn
IsradipineIsradipine may increase the antihypertensive activities of Barnidipine.Approved, Investigational
ItraconazoleThe serum concentration of Barnidipine can be increased when it is combined with Itraconazole.Approved, Investigational
KetanserinKetanserin may increase the antihypertensive activities of Barnidipine.Investigational
KetoconazoleThe serum concentration of Barnidipine can be increased when it is combined with Ketoconazole.Approved, Investigational
LabetalolLabetalol may increase the antihypertensive activities of Barnidipine.Approved
LacidipineLacidipine may increase the antihypertensive activities of Barnidipine.Approved, Investigational
LatanoprostLatanoprost may increase the antihypertensive activities of Barnidipine.Approved, Investigational
LercanidipineLercanidipine may increase the antihypertensive activities of Barnidipine.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Barnidipine is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Levobupivacaine.Approved, Investigational
LevodopaBarnidipine may increase the orthostatic hypotensive activities of Levodopa.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Barnidipine is combined with Levosimendan.Approved, Investigational
LinsidomineLinsidomine may increase the antihypertensive activities of Barnidipine.Experimental
LisdexamfetamineThe risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Barnidipine.Approved, Investigational
LisinoprilLisinopril may increase the antihypertensive activities of Barnidipine.Approved, Investigational
LofexidineLofexidine may increase the antihypertensive activities of Barnidipine.Approved, Investigational
LopinavirThe serum concentration of Barnidipine can be increased when it is combined with Lopinavir.Approved
LosartanLosartan may increase the antihypertensive activities of Barnidipine.Approved
MacitentanMacitentan may increase the antihypertensive activities of Barnidipine.Approved
Magnesium hydroxideThe risk or severity of hypotension and neuromuscular blockade can be increased when Barnidipine is combined with Magnesium hydroxide.Approved, Investigational
Magnesium oxideThe risk or severity of hypotension and neuromuscular blockade can be increased when Barnidipine is combined with Magnesium oxide.Approved
Magnesium salicylateThe risk or severity of hypotension and neuromuscular blockade can be increased when Barnidipine is combined with Magnesium salicylate.Approved
Magnesium sulfateThe risk or severity of hypotension and neuromuscular blockade can be increased when Barnidipine is combined with Magnesium sulfate.Approved, Investigational, Vet Approved
ManidipineManidipine may increase the antihypertensive activities of Barnidipine.Approved, Investigational
MannitolThe risk or severity of adverse effects can be increased when Barnidipine is combined with Mannitol.Approved, Investigational
MecamylamineMecamylamine may increase the antihypertensive activities of Barnidipine.Approved, Investigational
MepartricinThe therapeutic efficacy of Mepartricin can be increased when used in combination with Barnidipine.Experimental
MethazolamideThe risk or severity of adverse effects can be increased when Barnidipine is combined with Methazolamide.Approved
MethohexitalThe metabolism of Barnidipine can be increased when combined with Methohexital.Approved
MethoserpidineMethoserpidine may increase the antihypertensive activities of Barnidipine.Experimental
MethotrimeprazineThe risk or severity of hypotension can be increased when Methotrimeprazine is combined with Barnidipine.Approved, Investigational
MethyclothiazideThe risk or severity of adverse effects can be increased when Barnidipine is combined with Methyclothiazide.Approved
MethyldopaMethyldopa may increase the antihypertensive activities of Barnidipine.Approved
MethylphenobarbitalThe metabolism of Barnidipine can be increased when combined with Methylphenobarbital.Approved
MetipranololMetipranolol may increase the antihypertensive activities of Barnidipine.Approved
MetolazoneMetolazone may increase the antihypertensive activities of Barnidipine.Approved
MetoprololMetoprolol may increase the antihypertensive activities of Barnidipine.Approved, Investigational
MetyrosineMetyrosine may increase the antihypertensive activities of Barnidipine.Approved
MevastatinThe therapeutic efficacy of Mevastatin can be increased when used in combination with Barnidipine.Experimental
MibefradilMibefradil may increase the antihypertensive activities of Barnidipine.Investigational, Withdrawn
MicafunginThe therapeutic efficacy of Micafungin can be increased when used in combination with Barnidipine.Approved, Investigational
MiconazoleThe therapeutic efficacy of Miconazole can be increased when used in combination with Barnidipine.Approved, Investigational, Vet Approved
MiltefosineThe therapeutic efficacy of Miltefosine can be increased when used in combination with Barnidipine.Approved, Investigational
MinoxidilMinoxidil may increase the antihypertensive activities of Barnidipine.Approved, Investigational
MoexiprilMoexipril may increase the antihypertensive activities of Barnidipine.Approved
MonensinThe therapeutic efficacy of Monensin can be increased when used in combination with Barnidipine.Vet Approved
MorphineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Morphine.Approved, Investigational
MoxonidineMoxonidine may increase the antihypertensive activities of Barnidipine.Approved, Investigational
MuzolimineMuzolimine may increase the antihypertensive activities of Barnidipine.Experimental
MyxothiazolThe therapeutic efficacy of Myxothiazol can be increased when used in combination with Barnidipine.Experimental
NabiloneThe risk or severity of adverse effects can be increased when Barnidipine is combined with Nabilone.Approved, Investigational
NadololNadolol may increase the antihypertensive activities of Barnidipine.Approved
NafcillinThe therapeutic efficacy of Barnidipine can be decreased when used in combination with Nafcillin.Approved, Investigational
NaftifineThe therapeutic efficacy of Naftifine can be increased when used in combination with Barnidipine.Approved
NaftopidilNaftopidil may increase the antihypertensive activities of Barnidipine.Investigational
NatamycinThe therapeutic efficacy of Natamycin can be increased when used in combination with Barnidipine.Approved
NebivololNebivolol may increase the antihypertensive activities of Barnidipine.Approved, Investigational
NefazodoneThe serum concentration of Barnidipine can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Barnidipine can be increased when it is combined with Nelfinavir.Approved
NesiritideThe risk or severity of adverse effects can be increased when Barnidipine is combined with Nesiritide.Approved, Investigational
NicardipineNicardipine may increase the antihypertensive activities of Barnidipine.Approved, Investigational
NicergolineThe risk or severity of hypotension can be increased when Nicergoline is combined with Barnidipine.Approved, Investigational
NicorandilNicorandil may increase the antihypertensive activities of Barnidipine.Approved, Investigational
NifedipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Nifedipine.Approved
NifuratelThe therapeutic efficacy of Nifuratel can be increased when used in combination with Barnidipine.Experimental
NiguldipineNiguldipine may increase the antihypertensive activities of Barnidipine.Experimental
Nikkomycin ZThe therapeutic efficacy of Nikkomycin Z can be increased when used in combination with Barnidipine.Investigational
NilvadipineNilvadipine may increase the antihypertensive activities of Barnidipine.Approved, Investigational
NimodipineNimodipine may increase the antihypertensive activities of Barnidipine.Approved, Investigational
NisoldipineNisoldipine may increase the antihypertensive activities of Barnidipine.Approved
NitrendipineNitrendipine may increase the antihypertensive activities of Barnidipine.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Barnidipine is combined with Nitric Oxide.Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Barnidipine is combined with Nitroglycerin.Approved, Investigational
NitroprussideNitroprusside may increase the antihypertensive activities of Barnidipine.Approved, Investigational
Nitrous acidThe risk or severity of adverse effects can be increased when Barnidipine is combined with Nitrous acid.Approved, Investigational
NitroxolineThe therapeutic efficacy of Nitroxoline can be increased when used in combination with Barnidipine.Approved
NortriptylineThe risk or severity of hypotension can be increased when Nortriptyline is combined with Barnidipine.Approved
NystatinThe therapeutic efficacy of Nystatin can be increased when used in combination with Barnidipine.Approved, Vet Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Barnidipine is combined with Obinutuzumab.Approved, Investigational
OlanzapineThe risk or severity of hypotension can be increased when Olanzapine is combined with Barnidipine.Approved, Investigational
OlmesartanOlmesartan may increase the antihypertensive activities of Barnidipine.Approved, Investigational
OmapatrilatOmapatrilat may increase the antihypertensive activities of Barnidipine.Investigational
OmoconazoleThe therapeutic efficacy of Omoconazole can be increased when used in combination with Barnidipine.Experimental
OxiconazoleThe therapeutic efficacy of Oxiconazole can be increased when used in combination with Barnidipine.Approved
OxprenololOxprenolol may increase the antihypertensive activities of Barnidipine.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Barnidipine is combined with Paclitaxel.Approved, Vet Approved
PafuramidineThe therapeutic efficacy of Pafuramidine can be increased when used in combination with Barnidipine.Investigational
PaliperidoneThe risk or severity of hypotension can be increased when Paliperidone is combined with Barnidipine.Approved
PapaverineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Papaverine.Approved, Investigational
PargylinePargyline may increase the antihypertensive activities of Barnidipine.Approved
PenbutololPenbutolol may increase the antihypertensive activities of Barnidipine.Approved, Investigational
PentamidineThe therapeutic efficacy of Pentamidine can be increased when used in combination with Barnidipine.Approved, Investigational
PentobarbitalThe metabolism of Barnidipine can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
PentoliniumPentolinium may increase the antihypertensive activities of Barnidipine.Approved
PerindoprilPerindopril may increase the antihypertensive activities of Barnidipine.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Phenelzine.Approved
PhenobarbitalThe metabolism of Barnidipine can be increased when combined with Phenobarbital.Approved, Investigational
PhenoxybenzaminePhenoxybenzamine may increase the antihypertensive activities of Barnidipine.Approved
PhentolaminePhentolamine may increase the antihypertensive activities of Barnidipine.Approved
PinacidilPinacidil may increase the antihypertensive activities of Barnidipine.Approved
PindololPindolol may increase the antihypertensive activities of Barnidipine.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Barnidipine is combined with Pipamperone.Approved, Investigational
PizotifenThe risk or severity of hypotension can be increased when Pizotifen is combined with Barnidipine.Approved
Platelet Activating FactorPlatelet Activating Factor may increase the antihypertensive activities of Barnidipine.Experimental
PolythiazidePolythiazide may increase the antihypertensive activities of Barnidipine.Approved
PosaconazoleThe serum concentration of Barnidipine can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleThe risk or severity of adverse effects can be increased when Barnidipine is combined with Pramipexole.Approved, Investigational
PrazosinPrazosin may increase the antihypertensive activities of Barnidipine.Approved
PrimidoneThe metabolism of Barnidipine can be increased when combined with Primidone.Approved, Vet Approved
PromazineThe risk or severity of hypotension can be increased when Promazine is combined with Barnidipine.Approved, Vet Approved
PropericiazineThe risk or severity of hypotension can be increased when Propericiazine is combined with Barnidipine.Approved, Investigational
PropiomazineThe risk or severity of hypotension can be increased when Propiomazine is combined with Barnidipine.Approved
PropiverineThe risk or severity of hypotension can be increased when Propiverine is combined with Barnidipine.Approved, Investigational
PropofolThe risk or severity of adverse effects can be increased when Barnidipine is combined with Propofol.Approved, Investigational, Vet Approved
PropranololPropranolol may increase the antihypertensive activities of Barnidipine.Approved, Investigational
PyrrolnitrinThe therapeutic efficacy of Pyrrolnitrin can be increased when used in combination with Barnidipine.Experimental
QuetiapineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Quetiapine.Approved
QuinaprilQuinapril may increase the antihypertensive activities of Barnidipine.Approved, Investigational
QuinidineThe risk or severity of hypotension can be increased when Quinidine is combined with Barnidipine.Approved, Investigational
RacepinephrineThe risk or severity of hypotension can be increased when Racepinephrine is combined with Barnidipine.Approved
RadicicolThe therapeutic efficacy of Radicicol can be increased when used in combination with Barnidipine.Experimental
RamiprilRamipril may increase the antihypertensive activities of Barnidipine.Approved
RasagilineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Rasagiline.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Barnidipine is combined with Remifentanil.Approved
RemikirenRemikiren may increase the antihypertensive activities of Barnidipine.Approved
RescinnamineRescinnamine may increase the antihypertensive activities of Barnidipine.Approved
ReserpineReserpine may increase the antihypertensive activities of Barnidipine.Approved, Investigational
RifabutinThe risk or severity of hypotension can be increased when Rifabutin is combined with Barnidipine.Approved, Investigational
RifampicinThe risk or severity of hypotension can be increased when Rifampicin is combined with Barnidipine.Approved
RifapentineThe risk or severity of hypotension can be increased when Rifapentine is combined with Barnidipine.Approved, Investigational
RifaximinThe risk or severity of hypotension can be increased when Rifaximin is combined with Barnidipine.Approved, Investigational
RilmenidineRilmenidine may increase the antihypertensive activities of Barnidipine.Approved, Investigational
RiociguatRiociguat may increase the antihypertensive activities of Barnidipine.Approved
RisperidoneBarnidipine may increase the hypotensive activities of Risperidone.Approved, Investigational
RopiniroleThe risk or severity of adverse effects can be increased when Barnidipine is combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Ropivacaine.Approved
RotigotineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Rotigotine.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Barnidipine is combined with Sacubitril.Approved
Salicylhydroxamic AcidThe therapeutic efficacy of Salicylhydroxamic Acid can be increased when used in combination with Barnidipine.Experimental
Salicylic acidThe therapeutic efficacy of Salicylic acid can be increased when used in combination with Barnidipine.Approved, Investigational, Vet Approved
SaprisartanSaprisartan may increase the antihypertensive activities of Barnidipine.Experimental
SaquinavirThe serum concentration of Barnidipine can be increased when it is combined with Saquinavir.Approved, Investigational
SecobarbitalThe metabolism of Barnidipine can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Selegiline.Approved, Investigational, Vet Approved
SelexipagSelexipag may increase the antihypertensive activities of Barnidipine.Approved
SertaconazoleThe therapeutic efficacy of Sertaconazole can be increased when used in combination with Barnidipine.Approved, Investigational
SevofluraneThe risk or severity of adverse effects can be increased when Barnidipine is combined with Sevoflurane.Approved, Vet Approved
SilodosinThe risk or severity of hypotension can be increased when Silodosin is combined with Barnidipine.Approved
SinefunginThe therapeutic efficacy of Sinefungin can be increased when used in combination with Barnidipine.Experimental
SirolimusThe therapeutic efficacy of Sirolimus can be increased when used in combination with Barnidipine.Approved, Investigational
SitaxentanSitaxentan may increase the antihypertensive activities of Barnidipine.Approved, Investigational, Withdrawn
SotalolThe risk or severity of adverse effects can be increased when Barnidipine is combined with Sotalol.Approved
SpiraprilSpirapril may increase the antihypertensive activities of Barnidipine.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Barnidipine is combined with Spironolactone.Approved
StiripentolThe serum concentration of Barnidipine can be increased when it is combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Barnidipine is combined with Streptokinase.Approved, Investigational
SufentanilThe risk or severity of adverse effects can be increased when Barnidipine is combined with Sufentanil.Approved, Investigational
SulconazoleThe therapeutic efficacy of Sulconazole can be increased when used in combination with Barnidipine.Approved
TalinololTalinolol may increase the antihypertensive activities of Barnidipine.Investigational
TamsulosinThe risk or severity of hypotension can be increased when Tamsulosin is combined with Barnidipine.Approved, Investigational
TavaboroleThe therapeutic efficacy of Tavaborole can be increased when used in combination with Barnidipine.Approved, Investigational
TelaprevirThe serum concentration of Barnidipine can be increased when it is combined with Telaprevir.Approved, Withdrawn
TelithromycinThe serum concentration of Barnidipine can be increased when it is combined with Telithromycin.Approved
TelmisartanTelmisartan may increase the antihypertensive activities of Barnidipine.Approved, Investigational
TemocaprilTemocapril may increase the antihypertensive activities of Barnidipine.Experimental, Investigational
TerazosinThe risk or severity of hypotension can be increased when Terazosin is combined with Barnidipine.Approved
TerbinafineThe therapeutic efficacy of Terbinafine can be increased when used in combination with Barnidipine.Approved, Investigational, Vet Approved
TerconazoleThe therapeutic efficacy of Terconazole can be increased when used in combination with Barnidipine.Approved
TerlipressinTerlipressin may increase the antihypertensive activities of Barnidipine.Approved, Investigational
TetrahydropalmatineTetrahydropalmatine may increase the antihypertensive activities of Barnidipine.Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Barnidipine is combined with Thalidomide.Approved, Investigational, Withdrawn
TheodrenalineTheodrenaline may increase the antihypertensive activities of Barnidipine.Investigational
ThiamylalThe metabolism of Barnidipine can be increased when combined with Thiamylal.Approved, Vet Approved
ThiopentalThe metabolism of Barnidipine can be increased when combined with Thiopental.Approved, Vet Approved
ThioproperazineThe risk or severity of hypotension can be increased when Thioproperazine is combined with Barnidipine.Approved
ThioridazineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Thioridazine.Approved, Withdrawn
ThymolThe therapeutic efficacy of Thymol can be increased when used in combination with Barnidipine.Approved
TiboloneTibolone may increase the antihypertensive activities of Barnidipine.Approved, Investigational
TicrynafenTicrynafen may increase the antihypertensive activities of Barnidipine.Withdrawn
TimololTimolol may increase the antihypertensive activities of Barnidipine.Approved
TioconazoleThe therapeutic efficacy of Tioconazole can be increased when used in combination with Barnidipine.Approved
TizanidineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Tizanidine.Approved, Investigational
TolazolineTolazoline may increase the antihypertensive activities of Barnidipine.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Barnidipine is combined with Tolcapone.Approved, Withdrawn
TolciclateThe therapeutic efficacy of Tolciclate can be increased when used in combination with Barnidipine.Experimental
TolnaftateThe therapeutic efficacy of Tolnaftate can be increased when used in combination with Barnidipine.Approved, Investigational, Vet Approved
TolonidineTolonidine may increase the antihypertensive activities of Barnidipine.Experimental
TorasemideTorasemide may increase the antihypertensive activities of Barnidipine.Approved
TrandolaprilTrandolapril may increase the antihypertensive activities of Barnidipine.Approved
TranylcypromineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Tranylcypromine.Approved, Investigational
TravoprostTravoprost may increase the antihypertensive activities of Barnidipine.Approved
TrazodoneThe risk or severity of hypotension can be increased when Trazodone is combined with Barnidipine.Approved, Investigational
TreprostinilTreprostinil may increase the antihypertensive activities of Barnidipine.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Barnidipine is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Barnidipine is combined with Triamterene.Approved
TrichlormethiazideTrichlormethiazide may increase the antihypertensive activities of Barnidipine.Approved, Vet Approved
TrifluoperazineThe risk or severity of hypotension can be increased when Trifluoperazine is combined with Barnidipine.Approved, Investigational
TrimazosinTrimazosin may increase the antihypertensive activities of Barnidipine.Experimental
TrimethaphanTrimethaphan may increase the antihypertensive activities of Barnidipine.Approved, Investigational
TrimetrexateThe therapeutic efficacy of Trimetrexate can be increased when used in combination with Barnidipine.Approved, Investigational
TrimipramineThe risk or severity of hypotension can be increased when Trimipramine is combined with Barnidipine.Approved
UnoprostoneUnoprostone may increase the antihypertensive activities of Barnidipine.Approved, Investigational
UrapidilUrapidil may increase the antihypertensive activities of Barnidipine.Investigational
ValsartanValsartan may increase the antihypertensive activities of Barnidipine.Approved, Investigational
VerapamilThe risk or severity of adverse effects can be increased when Barnidipine is combined with Verapamil.Approved
VincamineVincamine may increase the antihypertensive activities of Barnidipine.Experimental
VinpocetineVinpocetine may increase the antihypertensive activities of Barnidipine.Investigational
VoriconazoleThe serum concentration of Barnidipine can be increased when it is combined with Voriconazole.Approved, Investigational
WortmanninThe therapeutic efficacy of Wortmannin can be increased when used in combination with Barnidipine.Experimental
XipamideXipamide may increase the antihypertensive activities of Barnidipine.Experimental
XylometazolineXylometazoline may increase the antihypertensive activities of Barnidipine.Approved, Investigational
ZiprasidoneThe risk or severity of hypotension can be increased when Ziprasidone is combined with Barnidipine.Approved
ZofenoprilZofenopril may increase the antihypertensive activities of Barnidipine.Experimental
ZuclopenthixolThe risk or severity of hypotension can be increased when Zuclopenthixol is combined with Barnidipine.Approved, Investigational
Food Interactions
Not Available

References

General References
  1. Malhotra HS, Plosker GL: Barnidipine. Drugs. 2001;61(7):989-96; discussion 997-8. [PubMed:11434453]
  2. Teramura T, Watanabe T, Higuchi S, Hashimoto K: Metabolism and pharmacokinetics of barnidipine hydrochloride, a calcium channel blocker, in man following oral administration of its sustained release formulation. Xenobiotica. 1997 Feb;27(2):203-16. doi: 10.1080/004982597240695 . [PubMed:9058533]
  3. van Zwieten PA: Pharmacological profile of barnidipine: a single optical isomer dihydropyridine calcium antagonist. Blood Press Suppl. 1998;1:5-8. [PubMed:9660520]
  4. Spieker C: Efficacy and tolerability of once-daily barnidipine in the clinical management of patients with mild to moderate essential hypertension. Blood Press Suppl. 1998;1:15-21. [PubMed:9660522]
  5. Wegener JW, Meyrer H, Rupp J, Nawrath H: Barnidipine block of L-type Ca(2+) channel currents in rat ventricular cardiomyocytes. Br J Pharmacol. 2000 Aug;130(8):2015-23. doi: 10.1038/sj.bjp.0703514. [PubMed:10952695]
  6. Vasexten (barnidipine hydrochloride modified release capsules) Summary of Product Characteristics [Link]
External Links
PubChem Compound
443869
PubChem Substance
310265132
ChemSpider
391959
BindingDB
50088384
ChEBI
135793
ChEMBL
CHEMBL2103761
Wikipedia
Barnidipine
ATC Codes
C08CA12 — Barnidipine
MSDS
Download (68.3 KB)

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)226MSDS
boiling point (°C)614.5MSDS
Predicted Properties
PropertyValueSource
Water Solubility0.004 mg/mLALOGPS
logP4.12ALOGPS
logP3.51ChemAxon
logS-5.1ALOGPS
pKa (Strongest Acidic)19.47ChemAxon
pKa (Strongest Basic)7.91ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area111.01 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity136.36 m3·mol-1ChemAxon
Polarizability51.03 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as dihydropyridinecarboxylic acids and derivatives. These are compounds containing a dihydropyridine moiety bearing a carboxylic acid group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Pyridines and derivatives
Sub Class
Hydropyridines
Direct Parent
Dihydropyridinecarboxylic acids and derivatives
Alternative Parents
Nitrobenzenes / Phenylmethylamines / Benzylamines / Nitroaromatic compounds / Aralkylamines / Dicarboxylic acids and derivatives / N-alkylpyrrolidines / Vinylogous amides / Enoate esters / Methyl esters
show 12 more
Substituents
Dihydropyridinecarboxylic acid derivative / Nitrobenzene / Nitroaromatic compound / Benzylamine / Phenylmethylamine / Aralkylamine / Monocyclic benzene moiety / Dicarboxylic acid or derivatives / N-alkylpyrrolidine / Benzenoid
show 31 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Voltage-gated calcium channel activity
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1C
Uniprot ID
Q13936
Uniprot Name
Voltage-dependent L-type calcium channel subunit alpha-1C
Molecular Weight
248974.1 Da
References
  1. Kwan YW, Bangalore R, Lakitsh M, Glossmann H, Kass RS: Inhibition of cardiac L-type calcium channels by quaternary amlodipine: implications for pharmacokinetics and access to dihydropyridine binding site. J Mol Cell Cardiol. 1995 Jan;27(1):253-62. [PubMed:7760349]
  2. Tikhonov DB, Zhorov BS: Structural model for dihydropyridine binding to L-type calcium channels. J Biol Chem. 2009 Jul 10;284(28):19006-17. doi: 10.1074/jbc.M109.011296. Epub 2009 May 5. [PubMed:19416978]
  3. Yamaguchi S, Okamura Y, Nagao T, Adachi-Akahane S: Serine residue in the IIIS5-S6 linker of the L-type Ca2+ channel alpha 1C subunit is the critical determinant of the action of dihydropyridine Ca2+ channel agonists. J Biol Chem. 2000 Dec 29;275(52):41504-11. doi: 10.1074/jbc.M007165200. [PubMed:11022040]
  4. Vasexten (barnidipine hydrochloride modified release capsules) Summary of Product Characteristics [Link]

Drug created on October 22, 2015 14:52 / Updated on July 02, 2018 19:13